Trump administration suggests unverified connection between autism and Tylenol ingredient exposure in pregnancy.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 22 2025
0mins
Should l Buy KVUE?
Source: CNBC
Trump Administration's Stance on Acetaminophen: The Trump administration has suggested a potential link between acetaminophen use during pregnancy and autism, prompting the FDA to consider updating safety labels and issuing warnings, despite existing scientific literature indicating no causal relationship.
Response from Health Officials and Kenvue: Health officials are advising caution in acetaminophen use during pregnancy, while Kenvue, the maker of Tylenol, disputes the claims and emphasizes the drug's safety when used as directed, highlighting the risks of untreated fever and pain during pregnancy.
Leucovorin Approval for Autism Treatment: The FDA has approved leucovorin for treating autism, specifically for children with cerebral folate deficiency, although it is not a cure and may only improve certain symptoms under medical supervision.
Controversy Over Vaccine and Autism Claims: The administration, led by Robert F. Kennedy Jr., is investigating potential causes of autism, including vaccines, despite extensive research debunking the vaccine-autism link, and has faced criticism for promoting unproven theories.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KVUE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KVUE
Wall Street analysts forecast KVUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KVUE is 18.86 USD with a low forecast of 17.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
1 Buy
7 Hold
0 Sell
Hold
Current: 18.130
Low
17.00
Averages
18.86
High
23.00
Current: 18.130
Low
17.00
Averages
18.86
High
23.00
About KVUE
Kenvue Inc. is a consumer health company. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kenvue to Announce Q4 and Full Year 2025 Financial Results
- Earnings Announcement Schedule: Kenvue Inc. will release its Q4 and full year 2025 financial results after market close on February 17, 2026, demonstrating the company's commitment to transparency.
- No Conference Call: Due to the pending transaction with Kimberly-Clark, Kenvue will not host a quarterly conference call to review its financial results, which may affect investors' immediate understanding of the company's financial health.
- Company Background: Kenvue Inc. is the world's largest pure-play consumer health company by revenue, featuring iconic brands such as Aveeno®, BAND-AID®, Johnson’s®, Listerine®, Neutrogena®, and Tylenol®, showcasing its leadership in the consumer health sector.
- Brand Influence: Kenvue's brands are science-backed and recommended by healthcare professionals globally, indicating a high level of trust and influence in the market, further solidifying its competitive position.
See More
High Yield Potential in Oil and Consumer Goods Stocks
- Chevron's Stable Returns: Chevron boasts a 4% dividend yield and has increased its dividend for 37 consecutive years, with plans to grow earnings per share and free cash flow by at least 10% by 2030 when Brent crude prices are at $70, providing a robust cushion amid oil price volatility.
- Strong Financial Foundation: Chevron expects to achieve free cash flow breakeven at $50 per barrel of Brent, demonstrating its solid financial health and ability to navigate market fluctuations, ensuring long-term returns for shareholders.
- Kimberly-Clark's Acquisition Strategy: Kimberly-Clark is acquiring Kenvue at a price below $100, aiming for completion by 2026; despite facing growth stagnation and cost pressures, the company is optimistic about achieving billions in annual cost synergies post-acquisition.
- Sustained Dividend Growth: On January 27, Kimberly-Clark announced an increase in its quarterly dividend from $1.26 to $1.28 per share, which, while modest, marks its 54th consecutive year of dividend increases, reinforcing its status as a Dividend King and appealing to income-seeking investors.
See More
Investment Opportunities in Chevron and Kimberly-Clark
- Chevron's Robust Dividends: Chevron offers a 4% dividend yield and has increased its payout for 37 consecutive years, with plans to grow earnings per share and free cash flow by at least 10% by 2030 at $70 Brent crude, demonstrating resilience amid oil price fluctuations.
- Kimberly-Clark's Acquisition Strategy: Kimberly-Clark announced the acquisition of Kenvue, expected to close by the end of 2026; despite initial challenges, the company is optimistic about achieving billions in annual cost synergies, which will drive future earnings growth.
- Sustainability of Kimberly-Clark's Dividends: Kimberly-Clark anticipates generating $1.7 billion in free cash flow in 2025, fully supporting its $1.66 billion in dividend payments, showcasing financial stability amid industry slowdowns.
- Investment Value Assessment: Kimberly-Clark's stock is currently priced below $100, marking a 12-year low; despite facing growth stagnation and cost pressures, its 5.2% dividend yield and a forward P/E ratio of 13.1 make it an undervalued quality stock.
See More
Investment Opportunities in Consumer Staples Stocks for 2026
- Market Performance Review: The S&P 500 has gained 78.3% from 2023 to 2025, while the consumer staples sector has only increased by less than 5%, indicating a potential contrarian investment opportunity for value investors amid the sector's underperformance.
- Procter & Gamble's Situation: Procter & Gamble faced a 14.5% stock price decline in 2025, and despite a slight recovery in early 2026, a 1% drop in sales volume and a 5% decrease in net earnings highlight significant challenges, with future growth expectations remaining weak.
- Kimberly-Clark's Acquisition Plan: Kimberly-Clark anticipates achieving $2.1 billion in annual cost synergies from its acquisition of Kenvue, and while short-term performance is lackluster, this strategy may provide better growth prospects in the long run, attracting value investors' interest.
- Dividend Appeal: Procter & Gamble and Kimberly-Clark offer dividend yields of 2.9% and 5%, respectively, with both companies having a long history of increasing dividends, providing stable cash flow for income-seeking investors despite market pressures.
See More
Market Outlook for Procter & Gamble and Kimberly-Clark
- Sales Strategy Shift: Procter & Gamble is focusing on increasing sales volumes rather than raising prices, despite a 14.5% stock decline in 2025; under new CEO leadership, the company aims to improve performance through volume growth, although it may face margin compression in the short term.
- Poor Financial Performance: P&G's Q2 report indicated a 1% decline in sales volume and flat organic sales growth, with 2026 EPS growth projected at only 1% to 6%, highlighting significant challenges in a weak demand environment.
- Kimberly-Clark's Acquisition Plans: Kimberly-Clark plans to diversify through the acquisition of Kenvue, expecting EPS growth within two years post-acquisition and $2.1 billion in annual cost synergies within three years, despite low near-term performance expectations.
- Dividend Appeal: Both P&G and Kimberly-Clark are attractive high-dividend stocks, with P&G yielding 2.9% and Kimberly-Clark at 5%, both having consistently increased dividends over the years, appealing to investors seeking passive income.
See More
Three Dividend Kings Worth Buying
- Abbott's Stability: Abbott Laboratories (ABT) has increased its dividend for 50 consecutive years, currently paying $2.52 per share with a yield of 2.4%, surpassing the S&P 500's 1.1%, indicating strong free cash flow and a diversified healthcare business that supports ongoing dividend payments.
- Target's Recovery Potential: Despite challenges like low-margin essential sales and theft, Target (TGT) is implementing turnaround strategies under new CEO Michael Fiddelke, which could drive stock recovery; with a dividend yield of 4.5%, it offers investors a reliable source of passive income.
- Johnson & Johnson's Growth Outlook: After spinning off its consumer health business, Johnson & Johnson (JNJ) focused on innovative medicine and medtech, achieving a 6% sales increase to over $94 billion last year, with adjusted EPS rising over 8%, indicating strong revenue growth potential and a dividend of $5.20 per share at a yield of 2.3%.
- Investment Value of Dividend Stocks: In the current market environment, dividend stocks like Abbott, Target, and Johnson & Johnson provide investors with a safe source of passive income, especially during market volatility, making them suitable for those seeking long-term stable returns.
See More
Kenvue to Announce Q4 and Full Year 2025 Financial Results
- Earnings Announcement Schedule: Kenvue Inc. will release its Q4 and full year 2025 financial results after market close on February 17, 2026, demonstrating the company's commitment to transparency.
- No Conference Call: Due to the pending transaction with Kimberly-Clark, Kenvue will not host a quarterly conference call to review its financial results, which may affect investors' immediate understanding of the company's financial health.
- Company Background: Kenvue Inc. is the world's largest pure-play consumer health company by revenue, featuring iconic brands such as Aveeno®, BAND-AID®, Johnson’s®, Listerine®, Neutrogena®, and Tylenol®, showcasing its leadership in the consumer health sector.
- Brand Influence: Kenvue's brands are science-backed and recommended by healthcare professionals globally, indicating a high level of trust and influence in the market, further solidifying its competitive position.
See More
High Yield Potential in Oil and Consumer Goods Stocks
- Chevron's Stable Returns: Chevron boasts a 4% dividend yield and has increased its dividend for 37 consecutive years, with plans to grow earnings per share and free cash flow by at least 10% by 2030 when Brent crude prices are at $70, providing a robust cushion amid oil price volatility.
- Strong Financial Foundation: Chevron expects to achieve free cash flow breakeven at $50 per barrel of Brent, demonstrating its solid financial health and ability to navigate market fluctuations, ensuring long-term returns for shareholders.
- Kimberly-Clark's Acquisition Strategy: Kimberly-Clark is acquiring Kenvue at a price below $100, aiming for completion by 2026; despite facing growth stagnation and cost pressures, the company is optimistic about achieving billions in annual cost synergies post-acquisition.
- Sustained Dividend Growth: On January 27, Kimberly-Clark announced an increase in its quarterly dividend from $1.26 to $1.28 per share, which, while modest, marks its 54th consecutive year of dividend increases, reinforcing its status as a Dividend King and appealing to income-seeking investors.
See More
Investment Opportunities in Chevron and Kimberly-Clark
- Chevron's Robust Dividends: Chevron offers a 4% dividend yield and has increased its payout for 37 consecutive years, with plans to grow earnings per share and free cash flow by at least 10% by 2030 at $70 Brent crude, demonstrating resilience amid oil price fluctuations.
- Kimberly-Clark's Acquisition Strategy: Kimberly-Clark announced the acquisition of Kenvue, expected to close by the end of 2026; despite initial challenges, the company is optimistic about achieving billions in annual cost synergies, which will drive future earnings growth.
- Sustainability of Kimberly-Clark's Dividends: Kimberly-Clark anticipates generating $1.7 billion in free cash flow in 2025, fully supporting its $1.66 billion in dividend payments, showcasing financial stability amid industry slowdowns.
- Investment Value Assessment: Kimberly-Clark's stock is currently priced below $100, marking a 12-year low; despite facing growth stagnation and cost pressures, its 5.2% dividend yield and a forward P/E ratio of 13.1 make it an undervalued quality stock.
See More
Investment Opportunities in Consumer Staples Stocks for 2026
- Market Performance Review: The S&P 500 has gained 78.3% from 2023 to 2025, while the consumer staples sector has only increased by less than 5%, indicating a potential contrarian investment opportunity for value investors amid the sector's underperformance.
- Procter & Gamble's Situation: Procter & Gamble faced a 14.5% stock price decline in 2025, and despite a slight recovery in early 2026, a 1% drop in sales volume and a 5% decrease in net earnings highlight significant challenges, with future growth expectations remaining weak.
- Kimberly-Clark's Acquisition Plan: Kimberly-Clark anticipates achieving $2.1 billion in annual cost synergies from its acquisition of Kenvue, and while short-term performance is lackluster, this strategy may provide better growth prospects in the long run, attracting value investors' interest.
- Dividend Appeal: Procter & Gamble and Kimberly-Clark offer dividend yields of 2.9% and 5%, respectively, with both companies having a long history of increasing dividends, providing stable cash flow for income-seeking investors despite market pressures.
See More
Market Outlook for Procter & Gamble and Kimberly-Clark
- Sales Strategy Shift: Procter & Gamble is focusing on increasing sales volumes rather than raising prices, despite a 14.5% stock decline in 2025; under new CEO leadership, the company aims to improve performance through volume growth, although it may face margin compression in the short term.
- Poor Financial Performance: P&G's Q2 report indicated a 1% decline in sales volume and flat organic sales growth, with 2026 EPS growth projected at only 1% to 6%, highlighting significant challenges in a weak demand environment.
- Kimberly-Clark's Acquisition Plans: Kimberly-Clark plans to diversify through the acquisition of Kenvue, expecting EPS growth within two years post-acquisition and $2.1 billion in annual cost synergies within three years, despite low near-term performance expectations.
- Dividend Appeal: Both P&G and Kimberly-Clark are attractive high-dividend stocks, with P&G yielding 2.9% and Kimberly-Clark at 5%, both having consistently increased dividends over the years, appealing to investors seeking passive income.
See More
Three Dividend Kings Worth Buying
- Abbott's Stability: Abbott Laboratories (ABT) has increased its dividend for 50 consecutive years, currently paying $2.52 per share with a yield of 2.4%, surpassing the S&P 500's 1.1%, indicating strong free cash flow and a diversified healthcare business that supports ongoing dividend payments.
- Target's Recovery Potential: Despite challenges like low-margin essential sales and theft, Target (TGT) is implementing turnaround strategies under new CEO Michael Fiddelke, which could drive stock recovery; with a dividend yield of 4.5%, it offers investors a reliable source of passive income.
- Johnson & Johnson's Growth Outlook: After spinning off its consumer health business, Johnson & Johnson (JNJ) focused on innovative medicine and medtech, achieving a 6% sales increase to over $94 billion last year, with adjusted EPS rising over 8%, indicating strong revenue growth potential and a dividend of $5.20 per share at a yield of 2.3%.
- Investment Value of Dividend Stocks: In the current market environment, dividend stocks like Abbott, Target, and Johnson & Johnson provide investors with a safe source of passive income, especially during market volatility, making them suitable for those seeking long-term stable returns.
See More
